NextCell Pharma (NXTCL) Q2 2025 earnings summary

Executive summary

• ProTrans cell therapy shows promising long-term efficacy and safety in type 1 diabetes, with new data indicating improved insulin production after six years in some patients.

• Cellaviva achieved record sales and strong market demand despite challenging economic conditions, reinforcing its leadership in stem cell banking.

• QVance, the new subsidiary, completed lab setup, gained international recognition, and is preparing to onboard customers for advanced therapy analysis services.

• NextCell maintains a strong financial position with low running costs, ongoing revenue from subsidiaries, and five active clinical trials.

Financial highlights

• Q2 operating income was 3.4 MSEK (up from 2.4 MSEK YoY), with Cellaviva contributing 3.2 MSEK.

• Net sales for Q2 reached 3.2 MSEK (up from 2.3 MSEK YoY); first half net sales were 6.1 MSEK (down from 6.6 MSEK YoY).

• Q2 loss after financial items improved to -8.2 MSEK (from -10.1 MSEK YoY); EPS was -0.11 SEK (vs. -0.29 SEK YoY).

• Cash and cash equivalents at period end were 26.3 MSEK (down from 30.4 MSEK YoY).

• Equity ratio increased to 83.5% (from 79.2% YoY).

Outlook and guidance

• Recruitment for the younger ProTrans-Young cohort (ages 7-11) is ongoing, with one-year data expected in H2 2026.

• QVance aims to commence customer onboarding and pursue a Good Manufacturing Practice license in the next quarter.

• Cellaviva plans to expand offerings in stem cell banking, genetic testing, and preventive health services.